

Asst. Prof. ERHAN APTULLAHOĞLU

Personal Information

Office Phone: [+90 228 214 2120](tel:+902282142120)

Email: erhan.aptullahoglu@bilecik.edu.tr

Web: <https://avesis.bilecik.edu.tr/erhan.aptullahoglu>

International Researcher IDs

ScholarID: Xca84vQAAAAJ

ORCID: 0000-0002-9400-0938

Publons / Web Of Science ResearcherID: AAR-4337-2020

ScopusID: 57189795451

Yoksis Researcher ID: 321412

Education Information

Doctorate, University of Newcastle Upon Tyne, Faculty of Medical Sciences, Centre for Cancer, England 2016 - 2020

Postgraduate, Istanbul University, Health Sciences Institute, Genetik (YI) (Tezli), Turkey 2012 - 2014

Undergraduate, Ege University, Mühendislik Fakültesi, Biyomühendislik Bölümü, Turkey 2007 - 2012

Foreign Languages

English, C1 Advanced

Dissertations

Doctorate, The MDM2-p53 signalling network and sf3b1 status in chronic lymphocytic leukaemia, University of Newcastle Upon Tyne, 2020

Postgraduate, JAK2V617F mutasyonunun altın nanoflares kullanılarak tespiti, Istanbul University, Sağlık Bilimleri Enstitüsü, Genetik (YI) (Tezli), 2014

Research Areas

Molecular Biology of Cancer

Academic Titles / Tasks

Assistant Professor, Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik, 2023 - Continues

Lecturer, Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik, 2020 - 2023

Academic and Administrative Experience

Erasmus Program Department Coordinator, Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik,

2022 - Continues

Bilecik Seyh Edebali University, 2022 - Continues

Adaptation/Exemption Committee Member, Bilecik Seyh Edebali University, Fen Bilimleri Enstitüsü, Biyoteknoloji, 2020 - Continues

Anabilim Dalı Akademik Kurul Üyesi, Bilecik Seyh Edebali University, 2020 - Continues

Deputy Director of the Center, Bilecik Seyh Edebali University, 2020 - Continues

Courses

Hayvan Hücre Kültürü ve Uygulamaları, Postgraduate, 2023 - 2024

Methods in Cancer Research, Postgraduate, 2022 - 2023

Kanser Araştırma Yöntemleri, Postgraduate, 2021 - 2022

Kanser Biyolojisi, Undergraduate, 2020 - 2021

Mesleki İngilizce, Undergraduate, 2020 - 2021

Moleküler Biyoloji II, Undergraduate, 2020 - 2021

Moleküler Biyolojide Uygulamalar I, Undergraduate, 2020 - 2021

Doku Kültürü, Undergraduate, 2020 - 2021

Sitogenetik, Undergraduate, 2020 - 2021

Moleküler Biyolojide Uygulamalar II, Undergraduate, 2020 - 2021

Kök Hücre Biyolojisi, Undergraduate, 2020 - 2021

Hayvan Embriyolojisi, Undergraduate, 2020 - 2021

Moleküler Biyoloji I, Undergraduate, 2020 - 2021

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.**
Gungordu S., Aptullahoglu E.
Investigational new drugs, 2024 (SCI-Expanded)
- II. **RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia**
Aptullahoğlu E., Nakjang S., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.
BIOMEDICINES, vol.12, no.7, pp.1-17, 2024 (SCI-Expanded)
- III. **SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.**
Aptullahoglu E., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., Lunec J.
International journal of molecular sciences, vol.24, no.14, 2023 (SCI-Expanded)
- IV. **Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition**
Aptullahoglu E., Ciardullo C., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., Lunec J.
International Journal of Molecular Sciences, vol.24, no.3, 2023 (SCI-Expanded)
- V. **p53 as a biomarker and potential target in gastrointestinal stromal tumors**
Wu C., Chen C., Huang W., Pan Y., APTULLAHOĞLU E., Yeh C., Lunec J.
Frontiers in Oncology, vol.12, 2022 (SCI-Expanded)
- VI. **In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology**
Sozer S., Aptullahoglu E., Shivarov V., Yavuz A. S.
International Journal of Laboratory Hematology, vol.41, no.4, 2019 (SCI-Expanded)
- VII. **Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells**

Ciardullo C., Aptullahoglu E., Woodhouse L., Lin W., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., Lunec J. *Haematologica*, vol.104, no.12, pp.2429-2442, 2019 (SCI-Expanded)

VIII. **Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma**

Wu C., Esfandiari A., Ho Y., Wang N., Mahdi A. K., Aptullahoglu E., Lovat P., Lunec J. *British Journal of Cancer*, vol.118, no.4, pp.495-508, 2018 (SCI-Expanded)

Books & Book Chapters

I. **Technical English for Bioengineering Students**

APTULLAHOĞLU E.

Cinius Yayınları, İstanbul, 2022

II. **Professional English for Molecular Biology Students**

APTULLAHOĞLU E.

Cinius Yayınları, 2021

Refereed Congress / Symposium Publications in Proceedings

I. **Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells**

Willmore E., APTULLAHOĞLU E., Zhao Y., Kyle S., Thomas H., Ahn M., Fazal L., Noble M., Hardcastle I., Howard S., et al.

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 September 2019

II. **The spliceosome inhibitor E7107 induces a dose-dependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes**

APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 September 2019

III. **E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes**

APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.

The 25th Biennial Congress of the European Association for Cancer Research (EACR25), Amsterdam, Netherlands, 30 June - 03 July 2018

IV. **Combined drug targeting of p53 negative regulation in cutaneous melanoma**

APTULLAHOĞLU E.

Workshop On Rare Diseases, İstanbul, Turkey, 03 December 2022

V. **Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells**

Wu C., Esfandiari A., Ho Y., Shepherd C., Mahdi A. K., APTULLAHOĞLU E., WenCheng Chang J., Lovat P., Lunec J. (AACR) 2017 Annual Meeting, Washington, Kiribati, 1 - 05 April 2017

VI. **Activation of p53 by the MDM2 Antagonist RG7388 in CLL Cells: Analysis of ExVivo Signalling, Cell Death and Gene Signature**

Willmore E., Ciardullo C., APTULLAHOĞLU E., Woodhouse L., Wallis J. P., Marr H., Lunec J.

The biennial International Workshop on Chronic Lymphocytic Leukemia, New York, United States Of America, 12 - 15 May 2017

VII. **The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia**

Ciardullo C., Woodhouse L., APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., Lunec J.
58th ASH Annual Meeting Exposition, San Diego, 3 - 06 December 2016, vol.128, pp.893

VIII. **Evaluating the effect of RG7388 and HDM201 as single agents in a panel of B-cell lines and CLL samples**

APTULLAHOĞLU E., Ciardullo C., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., Lunec J.
UK CLL Forum, Londrina, Brazil, 05 October 2016

IX. **Mineralogical and petrographical properties of the volcanic activities in the Sakarya Continent Turkey**

KİBİCİ Y., YILDIZ A., İLBEYLİ N., BAĞCI M., DEMİRBİLEK M., HATİPOĞLU M., APTULLAHOĞLU E.
The symposium on Eastern Anatolian Geology (DAJEO' 2015), Van, Turkey, 7 - 11 September 2015, pp.44-47

X. **In-Cell Detection By Flow Cytometry of JAK2 V617F Mutation Using Gold Nanoflares**

APTULLAHOĞLU E., Uslu I., Yavuz A. S., Shivarov V., Sozer S.
56th ASH Annual Meeting Exposition, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, pp.4586

Supported Projects

Aptullahoğlu E., Akpınar Borazan A., Gurbanov R., İzgördü H., TÜBİTAK Project, Investigating Pharmacological Inhibition of mTORC2 with JR-AB2-011 in Acute Lymphoblastic Leukemia Using Preclinical Methods, 2024 - 2025

Aptullahoğlu E., Kaygusuz E., TÜBİTAK Project, Investigating the Combined Targeting of MDM2 and STAT3 as a New Therapeutic Approach in Acute Lymphoblastic Leukemia, 2021 - 2024

Lunec J., Willmore E., Aptullahoğlu E., Ciardullo C., Civil Society Organizations of Other Countries Supported Project, TP53 mutation detection and functional status as predictive biomarkers to guide the treatment of CLL patients, 2015 - 2021

Lunec J., Aptullahoğlu E., Civil Society Organizations of Other Countries Supported Project, Biomarker assessment and therapeutic targeting of the MDM2-p53 signalling network in chronic lymphocytic leukaemia (CLL) - University of Newcastle Upon Tyne, 2015 - 2017

Aptullahoğlu E., Project Supported by Higher Education Institutions, JAK2 V617F Mutasyonunun Altın Nanoflares Kullanılarak Tespiti (İstanbul Üniversitesi BAP yüksek lisans projesi) , 2014 - 2014

TÜBİTAK Project, JAK2V617F Mutasyonunun Endotel Hücre Fonksiyonları Üzerindeki Rolü (Bursiyer araştırmacı), 2013 - 2014

Awards

Aptullahoğlu E., Uluslararası Bilimsel Yayınları Teşvik Ödülü, Tübitak, January 2022

Aptullahoğlu E., Telif Ödülü, Astex Pharmaceuticals, January 2020

Aptullahoğlu E., EACR2018 Travel Grant, The European Association For Cancer Research, January 2018

Aptullahoğlu E., ASH (American Society of Hematology) Annual Meeting - Abstract Achievement Award, The Wallace H. Coulter Foundation, January 2014

Aptullahoğlu E., Yurtdışı doktora öğrenimi bursu - Republic of Turkey Ministry of National Education PhD Scholarship, Milli Eğitim Bakanlığı, January 2014

Aptullahoğlu E., Yurtiçi Yüksek Lisans Bursu, Tübitak, January 2012